High Dose Melphalan and Etoposide for Hodgkin's Disease
Author Information
Author(s): P.R.A. Taylor, G.H. Jackson, A.L. Lennard, H. Lucraft, S.J. Proctor
Primary Institution: Royal Victoria Infirmary
Hypothesis
This study aimed to assess the safety and efficacy of using high dose melphalan and etoposide followed by autologous, non-cryopreserved marrow rescue in advanced Hodgkin's disease.
Conclusion
The study found that high dose melphalan and etoposide followed by autologous marrow rescue is effective and has low toxicity for patients with poor risk Hodgkin's disease.
Supporting Evidence
- Complete haematological reconstitution occurred in 16 out of 17 patients.
- None of the patients transplanted in first, second, or third complete remission have relapsed.
- Two patients transplanted in fourth relapse went into complete remission.
Takeaway
Doctors used strong medicine to help people with a serious illness called Hodgkin's disease, and it worked well without making them very sick.
Methodology
Seventeen patients underwent autologous bone marrow transplant using high dose melphalan and etoposide conditioning.
Limitations
The study was limited to a small sample size from a single center.
Participant Demographics
The participants included 8 females and 9 males with a median age of 28 years.
Want to read the original?
Access the complete publication on the publisher's website